BriaCell Therapeutics Corp. (BCTXZ)West Vancouver, Canada | NasdaqCM
0.17 USD
-0.03
(-15.507%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:56 a.m. EDT
The immediate outlook is severely bearish due to a catastrophic disconnect between the stock price and the company's book value. Trading at merely 6% of book value while reporting massive negative returns on assets and equity indicates a market that has priced out any hope of recovery, likely driven by the severe cash burn and lack of free cash flow. The recent clinical news regarding lung metastasis resolution offers a glimmer of operational progress, but without a capital structure that can support further development or a path to profitability, this remains a speculative gamble rather than an investment. There is no dividend income to offset the capital destruction, and the statistical models offer no predictive power given the insufficient price history. This is a high-risk situation where the fundamentals suggest continued distress rather than a turnaround. |
| Attribute | Value |
|---|---|
| Beta | 1.51 |
| Website | https://briacell.com |
| Attribute | Value |
|---|---|
| Address1 | Bellevue Centre |
| Address2 | Suite 300 235 -15th Street |
| Ask | 0.15 |
| Ask Size | 1 |
| Beta | 1.506 |
| Bid | 0.928 |
| Bid Size | 1 |
| Book Value | 3.318 |
| City | West Vancouver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.17 |
| Current Ratio | 7.072 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.2 |
| Day Low | 0.1501 |
| Display Name | BriaCell Therapeutics |
| Ebitda | -31,916,296 |
| Ebitda Margins | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 604 921 1898 |
| Fifty Two Week High | 0.2 |
| Fifty Two Week High Change | -0.030000001 |
| Fifty Two Week High Change Percent | -0.15 |
| Fifty Two Week Low | 0.1501 |
| Fifty Two Week Low Change | 0.019900009 |
| Fifty Two Week Low Change Percent | 0.13257834 |
| Fifty Two Week Range | 0.1501 - 0.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 7,859,562 |
| Free Cashflow | -20,042,076 |
| Full Exchange Name | NasdaqCM |
| Fullday Change | -0.031199992 |
| Fullday Change Percent | -17.209044 |
| Fullday Price | 0.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,025-04-25 |
| Language | en-US |
| Long Business Summary | BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada. |
| Long Name | BriaCell Therapeutics Corp. |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_262266102 |
| Net Income To Common | -30,675,262 |
| Open | 0.2 |
| Operating Cashflow | -30,824,896 |
| Operating Margins | 0.0 |
| Phone | 604 921 1810 |
| Previous Close | 0.2012 |
| Price Hint | 4 |
| Price To Book | 0.051235683 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.351 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.031199992 |
| Regular Market Change Percent | -15.506954 |
| Regular Market Day High | 0.2 |
| Regular Market Day Low | 0.1501 |
| Regular Market Day Range | 0.1501 - 0.2 |
| Regular Market Open | 0.2 |
| Regular Market Previous Close | 0.2012 |
| Regular Market Price | 0.17 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 17,105 |
| Return On Assets | -0.90841 |
| Return On Equity | -1.75255 |
| Sand P52 Week Change | 0.1570785 |
| Sector | |
| Sector Key | |
| Short Name | BriaCell Therapeutics Corp. War |
| Source Interval | 15 |
| State | BC |
| Symbol | BCTXZ |
| Total Cash | 22,804,424 |
| Total Cash Per Share | 2.621 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 17,105 |
| Website | https://briacell.com |
| Zip | V7T 2X1 |